366 related articles for article (PubMed ID: 37112840)
21. A Prototype-Pathogen Approach for the Development of Flavivirus Countermeasures.
Kuhn RJ; Barrett ADT; Desilva AM; Harris E; Kramer LD; Montgomery RR; Pierson TC; Sette A; Diamond MS
J Infect Dis; 2023 Oct; 228(Suppl 6):S398-S413. PubMed ID: 37849402
[TBL] [Abstract][Full Text] [Related]
22. Lipids and flaviviruses, present and future perspectives for the control of dengue, Zika, and West Nile viruses.
Martín-Acebes MA; Vázquez-Calvo Á; Saiz JC
Prog Lipid Res; 2016 Oct; 64():123-137. PubMed ID: 27702593
[TBL] [Abstract][Full Text] [Related]
23. Flaviviruses and Kidney Diseases.
Burdmann EA
Adv Chronic Kidney Dis; 2019 May; 26(3):198-206. PubMed ID: 31202392
[TBL] [Abstract][Full Text] [Related]
24. Cross-Reactive Immunity among Five Medically Important Mosquito-Borne Flaviviruses Related to Human Diseases.
Hou B; Chen H; Gao N; An J
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746683
[TBL] [Abstract][Full Text] [Related]
25. T Cells in Tick-Borne Flavivirus Encephalitis: A Review of Current Paradigms in Protection and Disease Pathology.
Stone ET; Pinto AK
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112938
[TBL] [Abstract][Full Text] [Related]
26. Recent advancement in flavivirus vaccine development.
Chang GJ; Kuno G; Purdy DE; Davis BS
Expert Rev Vaccines; 2004 Apr; 3(2):199-220. PubMed ID: 15056045
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.
Sandberg JT; Löfling M; Varnaitė R; Emgård J; Al-Tawil N; Lindquist L; Gredmark-Russ S; Klingström J; Loré K; Blom K; Ljunggren HG
PLoS Negl Trop Dis; 2023 Feb; 17(2):e0010616. PubMed ID: 36758067
[TBL] [Abstract][Full Text] [Related]
28. Production and Biomedical Application of Flavivirus-like Particles.
Krol E; Brzuska G; Szewczyk B
Trends Biotechnol; 2019 Nov; 37(11):1202-1216. PubMed ID: 31003718
[TBL] [Abstract][Full Text] [Related]
29. Mapping the diverse structural landscape of the flavivirus antibody repertoire.
Sevvana M; Kuhn RJ
Curr Opin Virol; 2020 Dec; 45():51-64. PubMed ID: 32801077
[TBL] [Abstract][Full Text] [Related]
30. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
Elong Ngono A; Shresta S
Front Immunol; 2019; 10():1316. PubMed ID: 31244855
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses.
Shoushtari M; Roohvand F; Salehi-Vaziri M; Arashkia A; Bakhshi H; Azadmanesh K
Hum Vaccin Immunother; 2022 Nov; 18(5):2079323. PubMed ID: 35714271
[TBL] [Abstract][Full Text] [Related]
32. Mosquito-Borne Flaviviruses and Current Therapeutic Advances.
Qian X; Qi Z
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746697
[TBL] [Abstract][Full Text] [Related]
33. Noncoding Subgenomic Flavivirus RNA Is Processed by the Mosquito RNA Interference Machinery and Determines West Nile Virus Transmission by Culex pipiens Mosquitoes.
Göertz GP; Fros JJ; Miesen P; Vogels CBF; van der Bent ML; Geertsema C; Koenraadt CJM; van Rij RP; van Oers MM; Pijlman GP
J Virol; 2016 Nov; 90(22):10145-10159. PubMed ID: 27581979
[TBL] [Abstract][Full Text] [Related]
34. Pathogenesis and virulence of flavivirus infections.
van Leur SW; Heunis T; Munnur D; Sanyal S
Virulence; 2021 Dec; 12(1):2814-2838. PubMed ID: 34696709
[TBL] [Abstract][Full Text] [Related]
35. Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives.
Cuevas-Juárez E; Pando-Robles V; Palomares LA
Vaccine; 2021 Nov; 39(48):6990-7000. PubMed ID: 34753613
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in flavivirus antiviral drug discovery and vaccine development.
Ray D; Shi PY
Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):45-55. PubMed ID: 18221133
[TBL] [Abstract][Full Text] [Related]
37. Flavivirus vaccines.
Stephenson JR
Vaccine; 1988 Dec; 6(6):471-80. PubMed ID: 2854336
[TBL] [Abstract][Full Text] [Related]
38. Different Cross-Reactivities of IgM Responses in Dengue, Zika and Tick-Borne Encephalitis Virus Infections.
Stiasny K; Malafa S; Aberle SW; Medits I; Tsouchnikas G; Aberle JH; Holzmann H; Heinz FX
Viruses; 2021 Mar; 13(4):. PubMed ID: 33807442
[TBL] [Abstract][Full Text] [Related]
39. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
[TBL] [Abstract][Full Text] [Related]
40. Review of -omics studies on mosquito-borne viruses of the Flavivirus genus.
Peinado RDS; Eberle RJ; Pacca CC; Arni RK; Coronado MA
Virus Res; 2022 Jan; 307():198610. PubMed ID: 34718046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
